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1INTRODUCTION
Anemia in pregnancy exists world over but is a very
common problem in most of the developing countries. Anemia is
major public health problem in economically disadvantaged
segments of population in developing countries.
In country like India it is frequently severe and contributes to
maternal morbidity and mortality. It deserves more attention than
what it is currently receiving. Recently lot of programmes have
been focused on safe motherhood but maternal anemia a
problem of great concern.
Gender discrimination also plays a major role in increasing
the prevalence of anemia in developing countries.
Magnitude of Problem
The world wide prevalence of anemia in pregnant women is
estimated at 51% WHO states that 35% to 75% of pregnant
women in developing countries and 18% of women in
industralised countries are anemic.
2In India, the incidence of anemia among expectant mothers
is alarmingly high with hemoglobin level less than 10 gm%, 15 to
30% of maternal deaths are due to anemia.
In areas where malaria and hookworm infestation is
endemic prevalence of anemia is high as 91%. The incidence of
anemia is adolescent girls in slum areas estimated to 98% this
adversely affect reproductive performance.
The prevalence of anemia has come down due to
fortification, prophylactic iron supplementation and better health
care programmes aimed at woman and children.
NEED FOR THE STUDY
Anemia is the most important complication in pregnancy in
the developing countries not only because of its greatly increased
incidence but also because of its severity (Agarwal et al., 1999).
Several studies reveal that socioeconomic cultural factors
influence dietary inadequacy during pregnancy which is attributed
to poor purchasing power, literacy, ignorance, regarding nutritive
value of readily available cheaper food stuffs, cultural taboos,
3superstitions and large family (Menon Krishna et al., 1995; Ruth
Bunnet and Brown Linding, 1993; Naik D. Jayashree, 1992).
Nutritional iron deficiency anemia is a serious problem in
pregnancy which affects 90% pregnant women.
Severe forms of anemia in the third trimester of pregnancy
are invariably associated with cardiac failure. Highest maternal
mortality rate in developing countries is due to severe anemia,
contributing to 20% death both, directly and indirectly. It is also
responsible for incidence of premature and low birth weight
babies thus increasing perinatal and infant mortality and
morbidity.
According to Hassan Masood (1991), anemia is prevalent
among 50% - 90% of pregnant women especially in India, which
is the number one killer. Despite considerable improvement and
awareness in the antenatal care in developing countries and
in spite of national anemia prophylaxis programme in India
anemia remains a problem of great concern with regard to
maternal morbidity, mortality and adverse outcome (Singh
Kishore et al., 1995).
4Due to the above stated reasons this study emphasis on
regular antenatal check up, to screen for anemia during every
check up detect it earlier so that it can be treated adequately
before the mother reaches term gestation. The goal of the
treatment is to increase the hemoglobin status as rapidly as
possible.
5AIM OF THE STUDY
To Compare
? The response in each group by observing the rise in
hemoglobin which can be a good predictor for oral
iron therapy.
? The side effects in both groups of drugs
? The patient compliance in both groups, and then by
assessing the efficacy of ferrous sulphate and
carbonyl iron in moderately anemic pregnant women,
belonging to 24 to 32 weeks of gestational age.
6REVIEW OF LITERATURE
Definition of Anemia
Anemia is a condition of low circulating hemoglobin (Hb) in
which the Hb concentration has fallen below a threshold lying at
two standard deviations all below the median of healthy
population of the same age, sex and stage of pregnancy.
WHO definition for diagnosis of anemia in pregnancy is a
Hb concentration of less than 11 gm / dl and a hematocrit of less
than 33%, although CDC (Centers for Disease control USA)
proposes a cutoff point of 10.5 gm/dl during the second trimester.
Severity of Anemia
The Indian Council of Medical research uses four
categories of anemia depending upon the hemoglobin levels in
their study are:
7S. NO Category Hb Status gm/dl
1. Mild 10-10.9
2. Moderate 7-10
3. Severe <7
4. Very Severe
(Decompensated)
<4
Causes of Anemia
I. Physiological Anemia or hydremia of pregnancy
II.  Pathological Anemia
a. Nutritional – Iron, Folic Acid ,Vit B12,
Protein.
b. Hemorrhagic.
Acute - Following bleeding in early
pregnancy., H/o abortion or vesicular mole
previously.
Chronic - Hookworm Infestation, bleeding
hemorrhoids, ulcerative colitis, malignancies.
8c. Hemolytic
Familial Hemoglobinopathies
Acquired Malaria, Severe Infection
d. Bone Marrow Insufficiency
Hypoplasia or aplasia due to radiation, drugs
(aspirin, indomethacin)
CAUSES OF NUTRITIONAL ANEMIA DURING PREGNANCY
Nutritional Anemia is believed to be the most widespread
nutritional disorders in the world. It essentially affects people in
developing countries According to WHO 500 million to I billion
individuals representing 15 to 20 percent of world’s population is
presently affected by this condition.
 According to WHO definition, the “nutritional Anemia”
encompasses all pathological conditions in which the blood
hemoglobin concentration drops to an abnormally low level owing
to a deficiency in one or several essential nutrients, regardless of
the cause of this deficiency.
9The etiology of nutritional deficiency of iron in developing
countries is multifactorial. The causes include nutritional
deficiency of iron, folate and vitamin B12. Secondary effects of
infections and parasitic infestation. An imbalance occur as a
result of low nutrient intake, poor absorption, increased demand
of nutrients during pregnancy, increased nutrient loss due to
repeated pregnancies, short birth interval and menstruation.
Dietary short coming are often associated with low socio
economic status and related to cooking and dietary habits, local
food taboos, ignorance, illiteracy and lack of knowledge regarding
nutrition (Van De, 1998).
The etiological factors of nutritional Anemia in pregnancy
a. Dietary factors.
b. Increased demand during pregnancy
c. Maternal causes
d. Sociocultural factors
e. Infections and infestation.
10
a) Dietary factors
Inadequate intake of food
a) Low nutrient intake is the commonest cause of
nutritional anemia.
b) Main nutrients involved in synthesis of hemoglobin are
iron, folic acid, Vit B12 and deficiency of these cause
anemia.
Low iron absorption
Poor absorption and utilization of iron in the body is one of
the causes of iron deficiency anemia during pregnancy.
Factors decrease Iron absorption
a) Phytates
b) Calcium
c) Tannins
d) Tea and coffee
e) Herbal drinks
f) Fortified iron supplements.
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b) Increased Demand during pregnancy
Increased Demand for nutrients is one of the major of
nutritional anemia during pregnancy (Bucksher et at., 1996). The
increased blood volume during pregnancy results in dilution of red
cells and a reduction in hemoglobin concentration. This dilutional
anemia is potentially accentuated by the increased demands of
iron folic acid leading to anemia.
Poor absorption of iron occurs due to the fact that Indian
Diet is predominantly cereal based.
Though Indian diet has adequate iron content 20–25
mg/day several factors inhibits absorption, the most important
being the phytate from the cereals. Deficiency of ascorbic acid
and calcium inhibits iron absorption.
Factor Affecting Absorption
Factors increase absorption
a)  Hydrochloric acid by favoring dissolution and
reduction of ferric iron.
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b)  Reducing substance like ascorbic acid, amino acids
containing sulphydryl radical, these reduce ferric to
ferrous iron.
c) Meat contain organic iron and increased HCL
secretion.
d) Food containing low phosphorus diet.
There is increased demand for iron as it is essential for the
synthesis of increased hemoglobin required for the greater
maternal blood as well as for the storage of iron in the fetus.
When the mother does not meet this demand, she may develop
features of iron deficiency anemia. It is need not only to
compensate the usual losses in urine, faeces, cutaneous
desquamation (around 0.5 – 1 mg per day) but also to cover the
various pregnancy related expenditure. Total 1000 mg of iron is
required. This represents an extremely large amount to meet. If
not looked after it can result in iron deficiency anemia
(Hercubury, 1991).
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The Requirements of iron is not confined only to those
aspects of the fetus but also the placenta, the enlarged uterus
and for increased volume that occurs during pregnancy.
The estimates of iron requirements are
Foetus : 400 mg
Placenta  : 100 mg
Uterus :  50 mg
Hb :  320 mg
Total :  870 mg
c) Maternal Causes
Depletion of nutrients occur in maternal body due to various
reasons. The women may have entered pregnancy with
compromised or absent iron stores. When further iron depletion
occurs with advancing gestation anemia results (Zuspan and
Huiligun, 1994).
In tropics frequent pregnancies are the common cause of
iron and folic acid deficiency anemia among pregnant mother
(Buckshae et al., 1999) from depletion occurs due to
14
uncompensated menstrual loses and chronic blood loss due to
repeated pregnancies.
Grand multipara is considered as one of the cause
contributing to nutritional anemia during pregnancy as it is
associated with increased incidence of disorders like
hypertension, antepartum hemorrhage and others. The co-
existing pathological condition like APH, PPH, abortions lead to
iron deficiency results in iron deficiency anemia (Buckshae et al.,
1996; Modak et al., 1996).
There are maternal causes which lead to nutritional anemia
during pregnancy. These are:
a) Anemia in multigravida or multipara is mainly due to
blood loss in previous deliveries or pregnancies.
b) Repeated abortions, APH, PPH.
c) Extra demand for iron, folic acid in multiple
pregnancy.
d) Short interval between pregnancies.
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i. Less storage of iron in the mothers body since it
is already utilized in previous pregnancies.
ii. There is no time for storage of iron in the body
for the next pregnancy.
d) Socio Cultural Factors
i) Poor socioeconomic Status.
 As the women continue to be a socially disadvantaged
group their poor status affects nutrition.
ii) Cultural belief, Cooking and Eating habits food taboos.
 Cultural practices play an important role in cause of
nutritional anemia in pregnancy. Because of taboos the
pregnant mothers, avoid meat, fish, egg, jaggery,
curds, milk and leafy vegetables. Over cooking of food,
washing of vegetables several time may lead to loss of
nutrients in the food. This may also lead to nutritional
anemia in pregnancy (Vande 1998).
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e) Infection and infestation
i) Hookworm infestation
Hookworm infestation is considered as one of the
cause of nutritional anemia among the pregnant
women (Agarwal et al., 1999).
Infestation with hookworm, roundworm and whipworm
cause or aggravate iron deficiency anemia
(Sephension, 1994).
Hookworm infestation also leads to the deficiency of
folic acid in pregnant women (Buckshae et al.,
1996).
ii) Malaria
Plasmodium falciparam cause profound anemia
during an acute infection among pregnant woman
(Agarwal et al., 1999).
Erythropolesis
In human embryo hemopoiesis is first evident in yolk sac at
2 months, liver at 3rd month and to some extent spleen between
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3rd and 6th month. Bone marrow activity begins by 4th and 6th
month, it completely take over the process of hemopoiesis.
At birth bones are filled with red marrow, by 7 years marrow
in long bones is less active, by age of 10 to 14 years fatty marrow
extends proximally and 18 years normal adult distribution of
marrow is in the skull, axial skeleton, pelvis shoulder, sternum
ribs and with extension of proximal ends of long bones.
Stages of Erythropoiesis
i) Basophyllic proerythroblast
ii) Early Normoblast
iii) Intermediate normoblast
iv) Late normoblast
v) Reticulocyte
vi) Erythrocyte
Kinetics of Erythropoiesis
The time taken for erythropoiesis in human beings is about
7 days. The first 5 Days are occupied by division and maturation
upto non nucleated reticulocytes in the marrow and the
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reticulocytes normally mature for another 24 hours in the
peripheral blood and spleen, after which it circulate for 120 days.
Since about 1% circulating erythrocytes are destroyed each day,
same number are formed and released. Factors regulating
erythropoiesis.
a) Androgen stimulates, esterogen suppresses
erythropoiesis,
b) Thyroid hormone and adrenocortical steroids
stimulates erythropotesis
c) Nutritional factors like proteins. Vit B12 folic acid , Vit
B6, riboflavin. Pantothenic acid, nicotinic acid, ascorbic
acid, Vit E, mineral like copper cobalt, zinc and iron.
IRON COMPARTMENTS IN HUMAN
Hemoglobin: 1ml of packed RBC contain 1mg of iron and
size of this compartment changes in anemia.
Storage: Ferritin and haemosiderin.
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Ferritin: It is a water insoluble complex of ferric
hydroxide and protein apoferritin. Uptake and release of iron by
ferritin is very rapid. Ferritin occurs in all cells of the body. Its
concentration correlates with iron store. Hemosiderin water
soluble compound found predominantly in cells of monocytes
macrophage system.
Myoglobin: Present in all skeletal and cardiac muscles
cells.
Transport Iron: Active transport process explained by
“Mucosal Block Theory”. According to this theory ferrous form
absorbed in small intestine converted to Ferric form in the
intestinal villi combine with apoferritin in the villous epithelial cell
to form ferritin. Absorption of iron is controlled by the availability
of apoferritin. If this is fully saturated no more iron is absorbed,
and this protects from excessive absorption in anemia. In anemia
excess ferritin is broken down to make more apoferritin available
and thereby augments iron absorption. This intracellular ferritin is
eventually excreted following desquamation of epithelial cells of
intestine.
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IRON TRANSPORT AND UTILIZATION
Iron after absorption circulate in the blood bounded to a
? globulin transferrin which is normally 1/3 saturated with iron.
Normal iron varies from 66 -140 microgram / 100 mg plasma.
Physiological changes in Hemoglobin during pregnancy
In pregnancy there is progressive increase in circulating
blood volume due to increase in plasma and RBC volume.
Increase blood volume ranges from 30 – 70% of the non
pregnant level.
Increase blood volume due to maternal size, level of
placental and extra placental hormones and erythropoietin,
influence the increase in blood volume.
The increase in plasma volume is 40 – 50%
The increase in RBC volume is 20%.
Anemia during pregnancy is a consequence of primarily of
expansion of plasma volume without normal expansion of
maternal hemoglobin.
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This is called physiological anemia because
i) It begins in second trimester when the iron needs are
fully met.
ii) Occurs in well nourished women
Physiological Anemia Occurs Because
i) Increase in plasma volume and RBC volume occur at
different periods of pregnancy.
ii) Plasma volume begins to rise at 6 -8 weeks of
pregnancy reaches peaks at about 32 weeks after it
plateaus.
iii) The rise in RBC volume begins at 20 weeks and
continue till term. There is trend for mean Hb fall in
the first and second trimester and little rise later in the
third trimester (Peck and Ariyes, 1979.)
Hematological parameters
Normal blood values in non pregnant status.
RBC - 4.8 - 6 million / cumm
Hb - 12 – 14 gm / dl
PCV - 40 – 45%
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Life span of RBC is 110 -120 days.
Normal blood values during pregnancy
RBC -  4.5 million / cumm
PCV -  37 – 42%
MCV -  80 – 90 cubic microns
MCHC - 28 – 34%
MCH - 27 – 32 picogram
Colour Index - 0.9 – 1
 Hb in gm per 1000ml blood
Mean corpuscular Hb MCH =
     RBC in million / cumm
Normal = 27 - 32 Picogram
  Volumes of packed cell per 1000ml
Mean corpuscular Hb MCV =
 RBC in million / cumm
Normal   =  80-90 cubic microns
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Mean corpuscular Hb = Hb in gm per 100 ml
           Concentration MCHC
___________________________    × 100
 Volumes of packed cell per 100ml
Normal = 34 percent
        Hb (percentage of normal)
Colour Index = _______________________
RBC  (percentage of normal)
Normal =  0.9 – 1
Symptoms and signs
Symptoms: complaints of fatigue, poor tolerance of
exertion, weakness and lassitude. Other features are anorexia
and indigestion, palpitation caused by ectopic beats, dyspnoea,
giddiness and swelling of legs.
Signs
Pallor
Pallor of varying degree is evident. The colour of the lips,
tongue, inner side of the lower eyelid, palms, and sole are pale. If
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the colour of palmar creases are as pale as the surrounding skin
the hemoglobin is usually less than 7 gm/dl.
Nailbed should be examined for pallor, the rapidity of
capillary refill is an indicator of integrity of the cardiovascular
system.
Koilonychia
Koilonychia is strongly suggestive of Iron deficiency and is
demonstrated as spoon shaped nails.
Glossitis
Ulceration in the mouth and tongue. The painful dry tongue
of glossitis is helpful in diagnosing Vit B12 deficiency anemia.
Angular stomatitis is also associated.
Oedema legs
This is due to hypoproteinemia.
25
Cardiovascular Changes
Cardiovascular signs reflect decompensation, a soft systolic
murmur may be heard in mitral area due to mitral incompetence.
Crepitations may be heard at the base of lungs due to
congestion.
Investigation
1. Maternal condition.
2. Fetal Condition.
Maternal condition:  a)Type and degree of severity.
The investigations include,
a)  Hb%
b)  RBC Count.
c) Blood indices.
MCV – Normal 78 -92 cu micron.
<78 microcytic suggest iron def.
>92 macrocytic follate def.
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MCH – Normal 28 -33 pgm.
? In iron deficiency anemia
MCHC – 33 – 36 %
? In iron deficiency anemia
Peripheral smear
MICROCYTIC HYPOCHROMIC BLOOD PICTURE
This is simple investigation often throws light on the etiology
a) Microcytic hypochromic cells.
b) Macrocytic hyperchromic cells.
c) Normocytic normochromic cells.
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1) Microcytic hypochromic calls are seen in
a) Iron deficiency.
b) Thalessemia.
c) Sideroblastic anemia.
d) Anemia of chronic disease.
e) Lead poisoning.
f) Copper poisoning.
2) Macrocytic hyperchromic cells.
a) Follate/ vit B12 deficiency.
3) Normocytic normochromic.
a) Other causes or early nutritional deficiency
4) Schisto / aniso and poikilocytes:
Hemolytic anemia.
5) Target cells:
Thelessemia.
6) Sickle cells.
Sickle cell anemia.
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7) Hypersegmented polymorphs.
Seen in megaloblastic anemia.
8) Platelet:
May be decreased.
9) Parasites:
Such as malaria and leishmania may be seen.
B) INVESTIGATION FOR ETIOLOGY
Urine examination :
Urine albumin, sugar and deposits, and urine culture and
sensitivity to rule out infection.
Stool examination :
- Parasites (ova of hookworm)
- Occult blood loss.
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C) SPECIAL INVESTIGATIONS
1. Ferrokinetics:
These are tests that confirm the diagnosis and
severity of iron deficiency anemia.
a) Serum ferritin
Normal - 15-300 ?g/l
Abnormal when <12 ?g/l
b)  Serum transferrin
Normal 300 – 360 g/ml value increases with
severity of anemia.
c)  Serum iron
Normal 65 – 165 µ gm/dl. It is decreased in iron
deficiency anemia.
d)  Percentage saturation of transferring -
                 Serum iron
 ________________________
    Total iron binding capacity
Normal 35-50%. This value is 15% in iron
deficiency anemia.
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e) RBC protoporphyrin – 30 gm/dl. This value is
found doubled or tribled.
f) Total iron binding capacity
Normal 350 – 400 ?g / 100 ml
Increased in iron deficiency anemia.
g) Free erythrocyte protoporphyrn (FEP): substrate
used for heam synthesis
Increased in iron deficiency anemia
Mild IDA - zinc protoporphyrin concentration
between 40–70 µ mol/ml
More advance IDA – ZPP is > 70 µ mol/ml
h) Serum Transferrin receptor measured by ELISA
This is new method to assess cellular iron
status. It is particularly valuable in identifying
iron deficiency anemia in pregnancy, since it is
the only measurement to accurately reflect the
iron deficit between the point of storage iron
depletion and development of anemia.
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2. Investigations in magaloblastic anemia.
a) MCV 110 – 140 cubic microns.
b) MCH 33 – 36 picograms.
c) Serum follate <3 ng/ml.
d) RBC follate <150 nm/ml.
e) Serum vit B12.
f) Peripheral smear macrocytic and
hypersegmented neutrophil.
g) Serum B12.
h) Buffy cost.
i) FIGLU test.
3. Investigations in hemolytic anemia.
a) Osmotic fragility.
b) Coombs test.
c) Hemoglobin electrophoresis.
4. Tests to ensure therapy.
1. Reticulocyte count – increases.
2. Hemoglobin – increases.
3. Peripheral smear - decrease in abnormal cell
type.
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5. Screening test
Hemoglobin must be determined by Sahils
hemoglobin method at the first antenatal visit. It
should be repeated in all antenatal visit ideally at 32
weeks gestation when their haemodilution is at its
peak.
Effects of nutritional anemia during pregnancy
Nutritional anemia among pregnant women is associated
with adverse consequences to both the mother and the foetus.
These adverse effects vary upon the severity of anemia and
presence of other obstetric or systemic problems in anemic
women (Lewis and Chamberlin 1999).
Effects on the mother
1) Iron deficiency anemia among pregnant women leads
to diminished work capacity, physical performance
and neurological dysfunction.
2) More prone for infections.
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3) Antepartum and postpartum haemorrhage are more
common in anemic mothers.
4) Antenatal mothers go for cardiac failure during labour.
5) Puerperal pyrexia.
6) Puerperal sepsis.
7) Subinvolution of uterus.
8) Lactational failure
9) Episiotomy wound gaping and abdominal wound
gaping.
 10) Abortion.
 11) Folate deficiency leads to PIH, abruptioplacenta
 12) Maternal and perinatal morbidity and mortality
increased in anemic mother
Effect on fetus
Nutritional anemia due to iron and folic acid deficiency is the
cause of abortion, premature birth, low birth weight, foetal
wastage like abortion, intrauterine death, and stillbirth occur in
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about 20% of the conception due to anemia (Sethi et al., 1991;
Kelton et al., 1988) IUGR, impaired learning ability in children.
? Folic acid deficiency has been implicated as a cause
of foetal malformation especially neural tube defects.
? Maternal iron deficiency anemia leads to lower iron
rescue in infancy.
? Severe nutritional anemia among pregnant mother
leads to increased risk of intrauterine hypoxia, higher
perinatal and neonatal mortality and morbidity.
PREVENTION OF IRON DEFICIENCY ANEMIA
Prophylaxis of non pregnant women
Girls in India are deprived of good diet. As most women
start their pregnancy with anemia or low iron stores, prevention
should start even before pregnancy. The women of childbearing
age should receive 60mg of iron daily for 2 – 4 months along with
folic acid to prevent neural tube defects.
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Iron supplementation during pregnancy
The ministry of health government of India now
recommended intake of 100mg of elemental iron 500 µgm folic
acid in the second half of pregnancy for a period of at least 100
days.
Treatment of hookworm infestation
Single dose albendazole 400mg or mebendazole 100 mg
twice daily for 3 days with iron supplementation should be given
to all anemic pregnant women.
4. Improvement of dietary habits
Pregnant woman should eat foods rich in iron jaggery,
green leafy vegetables like spinach, mustard leaves, turnip green,
cereals, sprouted pulses. Avoid tea and coffee intake, too much
cooking should be avoided.
5. Proper antenatal care
a) Antenatal mothers should have regular antenatal
checkup which should begin in first trimester of
pregnancy.
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b) Hb% estimation should be done during every A.N.
visit.
c) Iron and folic acid should be consumed daily.
d) Proper treatment of infection.
6. Health education
1. By limiting number of children 1 to 2.
2. The ideal interval between 2 successive pregnancy
should be 3 year.
3. Ideal age for child bearing is 20 – 25 yrs.
TREATMENT OF IRON DEFICIENCY ANEMIA
Oral iron therapy
If the women presents in mid trimester or early third
trimester with anemia oral iron is started. Plenty of iron
preparation are available each with own advantages and
disadvantages.
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Dosage
Ferrous sulphate tablets are used in all government hospital
for oral treatment of anemia. For treatment more than 180 mg of
elemental iron per day is required. Two tablets of ferrous sulphate
each containing 100 mg of elemental iron per day is required for
treatment.
Side effects
Upto 10% of women may have side effects with oral iron in
the form of gastrointestinal symptoms such as nausea, vomiting,
constipation, abdominal cramps and diarrhea, which are dose
related, side effects can be minimized by advising to take the
tablet with food.
Response to treatment
The patient’s response to 180 mg elemental iron per day is
fast with significant increase in Hb from 0.3 to 1 gm per week.
Reticulocytosis occur within 5 – 10 days of treatment.
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Duration of treatment
Treatment should be continued until the blood parameter
become normal after which a maintenance dose of 1 tablet per
day should be continued for at least 3 months after delivery.
Disadvantage of oral treatment
a) Intolerance of medication.
b) Noncompliance.
c) Unpredictable absorption.
d) Hemoglobin concentration restored with therapeutic
dose but replenishing iron stores required treatment
for longer periods.
If there is no significant clinical or hematological
improvement within 8 weeks diagnostic reevaluation is needed.
Reasons for failure to oral therapy involve inaccurate diagnosis of
other causes of microcytic anemia such as thalessemia,
phyridoxine deficiency, lead poisoning, continuous loss of blood
through hookworm infestation, co-existing infection, faulty iron
absorption concominant folate deficiency.
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          Carbonyl iron Conventional iron
a)  Ferrous sulphate
Ferrous sulphate available in government hospital contains
100 mg of elemental iron.
b) Carbonyl iron
The name Carbonyl iron comes from its process of
manufacturing. This is a pure form of elemental iron that contains
98% mineral iron which is a small particle preparation of highly
purified metallic iron. It is a form of elemental iron produced by a
chemical carbonyl decomposition process. Carbonyl describes
the process of manufacture of iron particles from iron penta
carbonyl gas.
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Features
Carbonyl iron is the purest form of iron; it is inert and hence
cannot be chelated.
Bioavailability
Carbonyl particles are small < 5µ and have large surface
areas which results in improved bioavailability.
Carbonyl iron has been shown to be well absorbed and
utilized in Hb synthesis. Its advantage includes environmental
stability.
Safety Profile
Carbonyl iron is much less toxic than ionized forms of iron.
In humans lethal dose of ferrous sulphate is 200 mg/kg. In recent
study no serious toxicity was reported in all patients with mean
carbonyl iron ingestion of 11.2 gm/kg.
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Side effects
Carbonyl iron does not have many of the side effects
associated with other iron product particularly ferrous sulphate
such as GI irritation, nausea, constipation or diarrhea. There was
no evidence of hematologic, hepatic or renal toxicity.
Advantages of carbonyl iron
i) It is 98% pure form. The percentage of elemental iron
in carbonyl iron is 100%.
ii) Unlike other preparation it is inert and incapable of
reacting with chelators of iron such as transferrin and
desferraxamine.
iii) It leads to rapid rise in hemoglobin.
iv) It is a wide margin of safety.
v) It is free from gastric side effect.
vi) It is safest in pregnancy.
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MANAGEMENT OF LABOUR IN ANEMIC PATIENTS
First Stage
Patient should be in a comfortable position. Sedation and
pain relief should be given. Oxygen should he kept ready and is
given if dyspnoea. In case of preterm labour, betamimitics and
steroids should be given with caution to avoid risk of pulmonary
oedema. Digitalization may be required in cardiac failure due to
anemia. The aim is to deliver vaginally.
Second Stage
The second stage is very stressful as the patients may go in
for cardiac failure. Prolongation of second stage can be curtailed
by forceps.
Third Stage
Third stage must be energetically treated as these patients
tolerate bleeding very poorly. Prophylactic methergin should be
given. Oxytocin 20 U infusion slowly given. Episiotomy wound
should be sutured faster.
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Puerperium
During puerperium mother should have adequate rest. Iron
and folate therapy should be continued for at least 3 months. Any
infection must  be energetically treated. The anemic patient
must use an effective method of contraception and should not
conceive for at least 2 years until the iron stores are replenished.
Sterilisation is preferred if the family is completed.
Several studies were done to compare the efficacy of
different treatment using oral and parentral iron.
A prospective partially randomized study of pregnancy
outcomes and hematologic responses to oral carbonyl iron
treatment in moderately anemic pregnant women This was done
in Moulana Azed Medical Collage, New Delhi, conducted by Jaib
Sharma, Sandya Jain, Venkatesan Malika, Tejinder Singh, Ashok
Kumar, This study compared the safety and efficacy in treating
pregnancy anemia with carbonyl iron and ferrous sulphate.
Changes in haemoglobin iron indicators, pregnancy outcomes
and birth weight were compared between the 2 groups. The result
obtained were serum ferritin concentration rise after carbonyl iron
treatment better than oral ferrous sulphate group.
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Similar other studies
1. “A novel regime carbonyl iron therapy” Srivastava
Aarthi, Tanden Prabha, Darvineta conducted in ICMR
Deparment of Obstetric and Gynaecology KGMU
Lucknow.
2. carbonyl iron the treatment of iron deficiency anemia
of pregnancy stein ML. Gunston KD, Mey RM.
3. New Schedule of carbonyl iron administration for
pregnant women Mahale AR. Shah SH.
Bioavailability of carbonyl iron a randomized double blind
study Devasthali SD. Gordeuk VR. Brittenham GM. Bravo JR,
Compared ferrous sulphate with carbonyl iron in blood donors.
The Study Showed bio availability of carbonyl iron was better with
carbonyl iron.
High does carbonyl iron in iron deficiency anemia a
randomized double blind trial Gordeuk, Britterbharm. The study
concluded that high dose carbonyl iron was well tolerated than
standard ferrous sulphate in higher dosage.
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MATERIALS AND METHODS
The study was conducted from April 2009 – September
2009 at Government RSRM Lying – Hospital attached to Stanely
Medical College, Chennai.
The antenatal women attending the antenatal OPD between
the gestational age of 24 – 32 weeks were screened for Hb status
and 200 antenatal women who were having Hb between
8 – 9.5 gm% were selected for the study.
Exclusion Criteria
1. Gastrointestinal bleeding or mal-absorption, Bleeding
piles and bleeding from any other site is excluded.
2. Previous blood transfusion
3. Recent administration of iron for treatment of anemia
4. Woman with parasitic infection
5. Multiple pregnancy
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6. Woman with diabetes, hypertension significant
medical complication such as heart disease or any
other systematic disease are excluded.
INCLUSION CRITERIA
? Gestational age 24 – 32 weeks of pregnancy
? Moderately anemic (Hb 8 to 9.5 gms %) pregnant
woman attending OPD at RSRM
INVESTIGATION PERFORMED
1. Hb estimation by Sahlis hemoglobinometer
2. Peripheral smear with Leishman Stain
3. Packed cell volume
4. Mean corpuscular volume
5. Mean corpuscular hemoglobin concentration
6. Motion ova and cyst
7. Bleeding time
8. Clotting time
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METHODOLOGY
In all pregnant woman included in the study a written
informed consent was obtained.
Both the groups were allocated in such a way that body
mass index, gestational age and hemoglobin status initially was
equal in both treatment groups.
After selection patient was subjected to detailed history &
physical examination.
All patient subjected to investigation like hemoglobin,
peripheral smear, packed cell volume, mean corpuscular volume,
mean corpuscular hemoglobin concentration, platelet count,
bleeding time, clotting time and motion ova cyst.
THE TWO TREATMENT GROUPS ARE
100 of selected Group A received ferrous sulphate one
tablet of 100 mg of elemental iron thrice a day with folic acid
0.5 mg one tablet per day.
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100 of selected Group B received carbonyl iron one tablet
of 100 mg of elemental iron twice a day with folic acid 0.5 mg one
tablet per day.
Patient evaluated apart from baseline at 2 weeks interval.
Clinical evaluation for anemic improvement like improvement in
appetite and well being was enquired.  Patient was also enquired
about the drug complications like gastritis and about the colour of
the stool.  Adverse effect if any reported, were noted and vital like
blood pressure and pulse rate were noted.  Patient should be
bring back the used empty pack.
At the end of 4 weeks, repeat hemoglobin and hemotocrit
estimation was done.  The results and data was analyzed with
statistical test.
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OBSERVATION AND RESULTS
Table 1
Group A Ferrous
Sulphate
Group B Carbonyl Iron
Initial Hb
gm % No. of
Patients
Percentage
No. of
Patients
Percentage
8 to 8.5 23 23% 25 25%
8.5 to 9 28 28% 28 28%
9 to 9.5 49 49% 47 47%
In this study in Group A ferrous sulphate 23% of patient had
initial Hb 8 - 8.5 gm%, 28% had 8.5 - 9 gm% and 49% had
9-9.5gm%.
In Group B carbonyl iron 25% of patient had initial Hb of
8-8.5 gm%, 28% had 8.5-9 gm% and 47% had 9-9.5 gm%.
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Table 2
Group A Ferrous
Sulphate
Group B Carbonyl Iron
Rise in Hb
gm % No. of
Patients
Percentage
No. of
Patients
Percentage
0.5 to 1 12 12% -
1 to 1.5 66 66% 34 34%
1.5 – 2 22 22% 54 54%
> 2 - 12 12%
The rise in Hb in ferrous sulphate group is 12% between
0.5 - 1 gm%, 66% had rise of 1 - 1.5 gm% and 22% had rise of
1.5 - 2 gm%.
In Group B carbonyl iron 34% of patient had rise of
1 - 1.5 gm%, 54% of patient had rise of 1.5 - 2 gm% and 12%
showed a rise of > 2 gm%.
Conclusion
P value of less than 0.001 indicates the difference in “Rise
in Hb” between ferrous sulphate group and carbonyl iron group is
highly significant (Significant at 1%).
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Table 3
Group A Ferrous
Sulphate
Group B Carbonyl IronInitial
Hematocrit
in % No. of
Patients
Percentage
No. of
Patients
Percentage
23 to 26 23 23% 25 25%
26 to 29 77 77% 75 75%
In this study 23% of patient had initial Hct of 23 - 26% and
77% of patient had Hct of 26 - 29% in ferrous sulphate group.
In carbonyl iron group 25% of patient had initial Hct of
23 - 26% and 75% of patient had 26 - 29%.
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Table 4
Group A Ferrous
Sulphate
Group B Carbonyl IronRise in
Hematocrit
in % No. of
Patients
Percentage
No. of
Patients
Percentage
1% to 4% 47 47% 12 12%
4% to 7% 53 53% 88 88%
In this study 47% of patient had rise in Hct of 1 - 4% and
53% of patient had rise of 4 - 7% of Hct in ferrous sulphate group.
In carbonyl iron group 12% had rise of 1 - 4% Hct and 88%
had rise of 4 - 7% of Hct.
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Table 5
RISE IN Hb gm % IN PATIENT WITH INITIAL Hb 8 TO 8.5 gm%
Hb Rise in gm
%
Group A – Ferrous
Sulphate
Group B – Carbonyl
Iron
0.5 to 1 6% 0
1 to 1.5 15% 12%
1.5 to 2 2% 11%
> 2 0 2%
This table shows in ferrous sulphate group 15% had a rise
of 1 - 1.5 gm%, 2% of the patient had rise of 1.5 - 2gm% and
none had rise of > 2 gm%.
In carbonyl group 12% had rise of 1 - 1.5 gm%, 11% had
rise of 1.5 - 2 gm% and 2% had rise of > 2 gm%.
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Table 6
RISE IN Hb gm %  IN PATIENT WITH INITIAL Hb 8.5 TO 9 gm%
Hb Rise in gm %
Group A – Ferrous
Sulphate
Group B – Carbonyl
Iron
0.5 to 1 3% 0
1 to 1.5 23% 10%
1.5 to 2 2% 17%
> 2 0 1%
In this table in ferrous sulphate group 23% of patient had
rise of Hb 1 - 1.5 gm% and 17% of patient in carbonyl iron had
rise of 1.5 - 2 gm% and 1% of the carbonyl group had rise of
> 2 gm%.
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Table 7
RISE IN Hb gm %  IN PATIENT WITH INITIAL Hb 9 TO 9.5 gm %
Hb Rise in gm
%
Group A – Ferrous
Sulphate
Group B – Carbonyl
Iron
0.5 to 1 3% 0
1 to 1.5 28% 12%
1.5 to 2 18% 26%
> 2 0 9%
In ferrous sulphate group 28% had rise of Hb 1 - 1.5 gm%,
18% had rise of 1.5 – 2 gm% and none had rise of > 2 gm%.
In carbonyl iron group 12% had rise of 1 – 1.5 gm%, 26% of
patient had rise of 1.5 - 2 gm% and 9% of patient had rise of
> 2 gm%.
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Table 8
GROUP A - Ferrous
Sulphate
GROUP B - Carbonyl
IronAdverse
effect No. of
Patients
Percentage
No. of
Patients
Percentage
Constipation 7 7% 4 4%
Diarrhea 3 3% 2 2%
Epigastric
Pain
16 16% 8 8%
Metallic
taste
8 8% 12 12%
Nil 62 62% 72 72%
Vomiting 4 4% 2 2%
The adverse effect in group A ferrous sulphate as follows:
16% had epigastric pain, 8% had metallic taste, 7% had
constipation, 3% had diarrhea and 4% had vomiting and 62% had
no side effects.
In Group B carbonyl iron 12% had metallic taste, 8% had
epigastric pain, 4% had constipation, 2% had vomiting and
diarrhea and 72% had no adverse effects.
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Table 9
GROUP A - Ferrous
Sulphate
GROUP B - Carbonyl
IronPeripheral
Smear No. of
Patients
Percentage
No. of
Patients
Percentage
Microcytic
Hypochromic
65 65% 58 58%
Normocytic
Hypochromic
18 18% 26 26%
Normocytic
Normochromic
17 17% 16 16%
65% of ferrous sulphate group and 58% of carbonyl iron
group had microcytic hypochromic anemia blood picture.
18% of ferrous sulphate and 26% of carbonyl iron had
normocytic hypochromic blood picture.
17% of ferrous sulphate and 16% of carbonyl iron had
normocytic normochromic blood picture.
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Bivariate Analysis
Comparison of Age between Ferrous Sulphate Group and Carbonyl
Iron Group
Group Statistics
25.1500 4.48651
24.5600 4.57114
GROUP
Ferrous Sulphate
Carbonyl Iron
AGE
Mean Std. Deviation
Independent Samples Test
.921 198 .358 .5900 -.67308 1.85308AGE
t df P-value
Mean
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
Conclusion: P-value  of  0.358  indicates  the  difference  in  Age
between Ferrous Sulphate Group and Carbonyl Iron Group is not
significant.
62
Comparison of Parity between Ferrous Sulphate Group and
Carbonyl Iron Group
PARITY_ * GROUP Crosstabulation
34 27 61
55.7% 44.3% 100.0%
34.0% 27.0% 30.5%
36 38 74
48.6% 51.4% 100.0%
36.0% 38.0% 37.0%
7 7 14
50.0% 50.0% 100.0%
7.0% 7.0% 7.0%
23 28 51
45.1% 54.9% 100.0%
23.0% 28.0% 25.5%
100 100 200
50.0% 50.0% 100.0%
100.0% 100.0% 100.0%
Count
% within PARITY_
% within GROUP
Count
% within PARITY_
% within GROUP
Count
% within PARITY_
% within GROUP
Count
% within PARITY_
% within GROUP
Count
% within PARITY_
% within GROUP
G2
G3
G4
Primi
PARITY_
Total
Ferrous
Sulphate Carbonyl Iron
GROUP
Total
Conclusion: P-value of 0.718(insignificant) indicates the
distribution of parity does not differ across Ferrous Sulphate Group and
Carbonyl Iron Group
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Comparison of Gestational Age between Ferrous Sulphate Group
and Carbonyl Iron Group
Group Statistics
27.7200 2.34448
28.2814 2.55750
GROUP
Ferrous Sulphate
Carbonyl Iron
GES_AGE
Mean Std. Deviation
Independent Samples Test
-1.618 198 .107 -.5614 -1.24559 .12279GES_AGE
t df P-value
Mean
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
Conclusion: P-value of 0.107 indicates the difference in
gestational age between Ferrous Sulphate Group and Carbonyl Iron
Group is insignificant.
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Comparison of Initial Hb between Ferrous Sulphate Group and
Carbonyl Iron Group
Group Statistics
8.7790 .38620
8.8660 .35653
GROUP
Ferrous Sulphate
Carbonyl Iron
INIT_HB
Mean Std. Deviation
Independent Samples Test
-1.655 198 .099 -.0870 -.19065 .01665INIT_HB
t df P-value
Mean
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
Conclusion: P-value of 0.099 indicates the difference in Initial Hb
between Ferrous Sulphate Group and Carbonyl Iron Group is insignificant
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Comparison of Final Hb between Ferrous Sulphate Group and
Carbonyl Iron Group.
Group Statistics
10.0950 .54576
10.4590 .55489
GROUP
Ferrous Sulphate
Carbonyl Iron
FINAL_HB
Mean Std. Deviation
Independent Samples Test
-4.677 198 .000 -.3640 -.51748 -.21052FINAL_HB
t df P-value
Mean
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
Conclusion: P-value of less than 0.001 indicates the difference
in Final Hb between Ferrous Sulphate Group and Carbonyl Iron Group is
highly significant(significant at 1%).
.001
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Comparison of Rise in Hb between Ferrous Sulphate Group and
Carbonyl Iron Group.
Group Statistics
1.3190 .30141
1.6080 .28909
GROUP
Ferrous Sulphate
Carbonyl Iron
RISE_HB
Mean Std. Deviation
Conclusion: P-value of less than 0.001 indicates the difference in
“Rise in Hb” between Ferrous Sulphate Group and Carbonyl Iron Group is
highly significant (significant at 1%).
Independent Samples Test
-6.920 198 .001 -.2890 -.37136 -.20664RISE_HB
t df P-value
Mean
Difference Lower Upper
95% Confidence
Interval of the
Difference
t-test for Equality of Means
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DISCUSSION
Anemia is the commonest medical disorder in pregnancy.
Iron deficiency can be corrected by administration of iron. The
goal of treatment is to identify anemia at an earlier gestational
age and treatment should be aimed at increasing hemoglobin
level as rapidly as possible so as to decrease the maternal and
fetal morbidity and mortality.
Ferrous sulphate iron tablet is available  in all government
hospitals and hence the result obtained with Ferrous sulphate
and corbonyl iron were compared.
In my study only moderately anemic pregnant patients were
selected due to ethical reasons that severely anemic pregnant
women needs blood transmission.
In both groups majority of the patients had microcytic
hypochromic blood picture followed by normocytic hypochromic
blood picture.
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In my study Carbonyl Iron showed a better rise in Hb
percentage than ferrous sulphate (P value 0.001) which is
significant at 1%. This is consistent with the observation made by
Adul BB, Desai A, Gawde A, Baliga B in which there was a
significant increase in average Hb level (P<0.05) which was
significant at 1% from J. Indian Medical Association June 2005;
103 (6).
The better rise of Hb in Carbonyl Iron group could also be
attributed to increase in Bioavailability of Carbonyl Iron as
suggested  by Devasthali SD, Godeuk VR, Brittenham GM from
American Journal of clinical nutrition 1987 that overall bio
availability of Carbonyl iron was high above 70% of
ferrousulphate.
In my study the rise of Hb with short term therapy (4 weeks)
was better than ferrous sulphate (P value 0.001). This is similar to
the study by GOR Godeuk VR, Brittenhan Bravo J, Hughes MA,
Keating LJ 1990 March which concluded that short terms iron
supplement was effective against iron deficiency anemia with
(P value 0.001).
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In my study rise in Hb was a good predictor for the
response of iron treatment in anemic  pregnant women. This is
similar to the observation made by Freire WB Am J Clin Nutr
1989 Dec.
The adverse effect profile was in favor of carbonyl iron in
my study with less gastrointestinal  toxicity  this was similar to the
study by Gordeuk VR Brittenham GM,  Mclaren CE, Hughes Ma,
Keating LJ March 1986.
With respect to cost benefit analysis  the cost of ferrous
sulphate tablets accounts to Rs. 75/- for 1 month. The cost of
carbonyl iron for 1 month amounts ti Rs. 240/- for 1 month. Hence
in affordable group carbonyl iron is preferred.
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SUMMARY
In my study 54% of Carbonyl iron group showed a rise of
1.5-2 gm % and 12% showed a rise of more than 2 gm % of
hemoglobin whereas in ferrous sulphate group 66% showed a
rise of 1-1.5 gm % and 22% showed a rise of 1.5-2gm % and
none showed a rise of more than 2 gm % hemoglobin
? Rise in hemoglobin percentage was better with
carbonyl iron than ferrous sulphate.
? Carbonyl iron had less toxic to gastrointestinal
mucosa.
? Patients compliance was better with carbonyl iron.
? It is safer than ferrous sulphate as there is less risk of
causing poisoning due to over dosage.
? Carbonyl iron is inert and consists of small particles of
metallic iron.
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CONCLUSION
This study shows that the efficacy of carbonyl iron is
significantly more than ferrous sulphate, even though the relative
cost is more.
Affordable persons can be offered carbonyl iron.
In resource poor settings effective treatment of moderate
anemia is possible with ferrous sulphate if diagnosed at an earlier
stage.
Further large scale studies will raise the curtain for a better
understanding of the effect of different iron preparation on
different types of anemia.
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